National Centre on Addiction and Doping, Istituto Superiore di Sanità, Rome, Italy.
University of Camerino, Camerino, Italy.
Talanta. 2020 Mar 1;209:120537. doi: 10.1016/j.talanta.2019.120537. Epub 2019 Nov 15.
Monitoring pharmacological active compounds in pharmaceutical preparations of medical cannabis and in conventional and non-conventional biological matrices of treated individuals use requires both a wide linear range and sensitive detection. We have developed and validated a fast and sensitive method using ultra-high performance liquid chromatography coupled with tandem mass spectrometry (UHPLC-MS/MS) for analysis of Δ-9-tetrahydrocannabinol (THC), cannabidiol (CBD), their acidic precursors Δ-9-tetrahydrocannabinolic acid A (THCA-A) and cannabidiolic acid (CBDA) and some major metabolites of THC such as 11-nor-9-carboxy-THC (THC-COOH), 11-hydroxy-THC (11-OH-THC), Δ-9-THC-Glucuronide (THC-GLUC) and THC-COOH-Glucuronide (THC-COOH-GLUC) in conventional (whole blood and urine) and non-conventional (oral fluid and sweat) of individual treated with medical cannabis preparation. Specifically, THC, THCA-A, CBD and CBD-A were determined in cannabis decoction and oil prepared to treat individuals. The method used positive electrospray ionization (ESI) mode to reach the sensitivity needed to detect minimal amounts of analytes under investigations exposure with limits of quantification ranging from 0.2 to 0.5 ng per milliliter (ng/mL) or ng per patch in case of collected sweat. The validation results indicated this method was accurate (average inter/intra-day error, <10%), precise (inter/intra-day imprecision, <10%), and fast (10 min run time). In addition, time-consuming sample preparation was avoided applying dilute and shoot procedure, meeting the needs for potential large-scale population studies. The analysis of real samples demonstrated a pharmacokinetics of cannabinoids, their precursors and their metabolites dependent from quantity of carboxylated and decarboxylated compounds in pharmaceutical preparations.
监测药用大麻制剂以及经治疗个体的常规和非常规生物基质中的药理活性化合物既需要较宽的线性范围,又需要高灵敏度检测。我们开发并验证了一种使用超高效液相色谱与串联质谱(UHPLC-MS/MS)快速灵敏检测Δ-9-四氢大麻酚(THC)、大麻二酚(CBD)、其酸性前体Δ-9-四氢大麻酸 A(THCA-A)和大麻二酚酸(CBDA)以及 THC 的一些主要代谢物(如 11-去甲-9-羧基-THC(THC-COOH)、11-羟基-THC(11-OH-THC)、Δ-9-THC-葡糖苷酸(THC-GLUC)和 THC-COOH-葡糖苷酸(THC-COOH-GLUC))的方法,该方法可用于常规(全血和尿液)和非常规(口腔液和汗液)生物基质。具体而言,我们检测了用于治疗个体的大麻汤剂和油剂中的 THC、THCA-A、CBD 和 CBDA。该方法采用正电喷雾电离(ESI)模式,以达到检测研究中最小暴露量分析物所需的灵敏度,检测限范围为 0.2 至 0.5ng/mL(ng/mL)或采集汗液时的 0.5ng/贴。验证结果表明,该方法准确(日内/日间平均误差<10%)、精确(日内/日间精密度<10%)且快速(10 分钟运行时间)。此外,通过采用稀释和进样程序,避免了耗时的样品制备,满足了潜在大规模人群研究的需求。实际样品分析结果表明,药用制剂中羧基化和脱羧化合物的数量决定了大麻素及其前体和代谢物的药代动力学。